硼替佐米联合地塞米松治疗老年多发性骨髓瘤的疗效及对免疫抑制因子、免疫细胞水平的影响效果观察  

Efficacy of Bortezomib combined with Dexamethasone for the treatment of senile multiple myeloma and impact effect observation on the levels of immunosuppressive factors and immune cells

作　　者：刘昌勋 李术霞 侯艳秋 彭亚兰 王莉 甘露双 秦慧 鸿捷 LIU Chang-xun,LI Shu-xia, HOU Yan-qiu, et al.(Department of Hematology, Hulunbuir People＇s Hospital, Hulunbuir 021008, China)

机构地区：[1]呼伦贝尔市人民医院血液科,021008

出　　处：《中国实用医药》2018年第29期109-111,共3页China Practical Medicine

摘　　要：目的研究硼替佐米联合地塞米松治疗老年多发性骨髓瘤的临床效果及对患者免疫抑制因子和免疫细胞水平的影响。方法 40例老年多发性骨髓瘤患者,随机分为对照组和试验组,各20例。对照组患者给予长春新碱、地塞米松与表柔比星治疗,试验组患者给予硼替佐米联合地塞米松治疗。比较两组患者的临床疗效、治疗前后免疫抑制因子[白细胞介素(IL)-6、IL-17和转化生长因子-β(TGF-β)]水平及免疫细胞(CD3^+CD4^+、CD3^+CD8^+及CD3^+CD4^+/CD3^+CD8^+)水平。结果试验组治疗总有效率为95.00%,高于对照组的65.00%,差异有统计学意义(P<0.05)。治疗前两组免疫抑制因子水平比较差异无统计学意义(P>0.05);治疗后两组免疫抑制因子水平均低于治疗前,且试验组低于对照组,差异有统计学意义(P<0.05)。治疗前两组免疫细胞水平比较差异无统计学意义(P>0.05);治疗后两组免疫细胞水平均优于治疗前,且试验组优于对照组,差异有统计学意义(P<0.05)。结论硼替佐米联合地塞米松治疗老年多发性骨髓瘤的疗效显著,且能明显改善患者免疫抑制因子和免疫细胞水平,值得推广应用。Objective To research the clinical effect of Bortezomib combined with Dexamethasone for the treatment of senile multiple myeloma and influence of the levels of immunosuppressive factor and immune cell on patients. Methods A total of 40 elderly patients with multiple myeloma were randomly divided into control group and experimental group, 20 cases in each group. Patients in the control group were given Vincristine combined with Dexamethasone and Epirubicin for treatment, patients in the experimental group were given Bortezomib combined with Dexamethasone for treatment. The clinical efficacy, the levels of immunosuppressive factors [interleukin（IL）-6, IL-17 and transforming growth factor β（TGF-β）] and immune cells（CD3^＋CD4^＋, CD3^＋CD8^＋ and CD3^＋CD4^＋/CD3^＋CD8^＋） before and after treatment between the two groups were compared. Results The total effective rate of the experimental group was 95.00%, which was significantly higher than 65.00% of the control group, the difference was statistically significant（P〈0.05）. There were no significant differences in the levels of immunosuppressive factors between the two groups before treatment（P〉0.05）. The levels of immunosuppressive factors in the two groups after treatment were significantly lower than those before treatment, and above indexes of the experimental group were significantly lower than those of the control group, the differences were statistically significant（P〈0.05）. There were no significant differences in the levels of immune cells between the two groups before treatment（P〉0.05）. After treatment, the levels of immune cells in the two groups were significantly better than those before treatment, and above indexes of the experimental group were significantly better than those of the control group, the differences were statistically significant（P〈0.05）. Conclusion The efficacy of Bortezomib combined with Dexamethasone for the treatment of senile multiple myeloma is significant, it can significantly impr

关 键 词：硼替佐米 地塞米松 老年多发性骨髓瘤 

分 类 号：R733.3[医药卫生—肿瘤]